ALMS vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 16, 2026

ALMS

42.0
AI Score
VS
DNA Wins

DNA

44.7
AI Score

Investment Advisor Scores

ALMS

42score
Recommendation
HOLD

DNA

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ALMS DNA Winner
Revenue 3.40M 39.63M DNA
Net Income -235.27M -129.30M DNA
Net Margin -6913.7% -326.3% DNA
Operating Income -247.26M -129.92M DNA
ROE -52.0% -30.8% DNA
ROA -42.0% -13.1% DNA
Total Assets 560.62M 990.05M DNA
Cash 63.71M 84.53M DNA
Current Ratio 6.74 4.57 ALMS
Free Cash Flow -168.98M -95.51M DNA

Relative Price Performance (Last 90 Days)

ALMS 1M: -8.1% · 3M: -75.6% DNA 1M: +13.9% · 3M: +32.7%

Current Technical Phase

ALMS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -40.9%), weak momentum, RSI 34

RSI (14): 33.9 · Price: $6.84

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.8 · Price: $9.77

Fundamentals Snapshot

Metric ALMS DNA
Market Cap — —
Forward P/E -2.4 -3.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.4% -0.5%
Gross Margin 1.0% 0.7%
Operating Margin -64.4% -2.8%
EPS -3.86 -5.06
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.